drugset / Trial / NCT02173795

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

NCT02173795

Phase 3 Completed 245 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this study was to investigate patients acceptability / preference of Berodual® Respimat® inhaler as compared to the conventional Berodual® Metered Aerosol (MA) inhaler. Ease of handling and assembling the Respimat® inhaler at home under real life conditions was also evaluated.

Timeline

Start
2002-10
Primary completion
2003-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenoterol Unknown 50 ug Inhaled
Subject Fenoterol Unknown 50 ug
Subject Ipratropium Small molecule 20 ug Inhaled
Subject Ipratropium Small molecule 20 ug